Microsoft-backed OpenAI has finalized a deal that places its value at a staggering $80 billion or more. According to a report by The New York Times on Friday, sources familiar with the transaction revealed the details.
The deal involves the sale of existing shares through a tender offer spearheaded by venture firm Thrive Capital. This arrangement enables employees to liquidate their shares in the company, deviating from the conventional route of fundraising to inject capital into the business, as per the report.
OpenAI, known for its cutting-edge advancements in artificial intelligence, did not immediately respond to requests for comment from Reuters.
Read more: UK Competition Watchdog Investigates Microsoft-OpenAI Partnership
This recent deal echoes a similar agreement struck early last year. Venture-capital heavyweights Thrive Capital, Sequoia Capital, Andreessen Horowitz, and K2 Global came together to purchase OpenAI shares in a tender offer, placing the company’s valuation at approximately $29 billion, according to the report.
The emergence of OpenAI’s ChatGPT in late 2022 has spurred significant excitement and interest in the field of AI, prompting companies across industries to explore innovative ways to leverage the technology’s capabilities.
This latest valuation reflects the growing recognition of AI’s potential to revolutionize various sectors, from healthcare to finance, and beyond. With OpenAI at the forefront of AI research and development, backed by the support of industry giants like Microsoft, the company’s trajectory continues to capture the attention of investors and industry observers alike.
As AI continues to evolve and permeate further into our daily lives, deals of this magnitude underscore the immense value placed on companies at the forefront of this technological revolution.
Source: Reuters
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI